Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis

Corrie L. Poelman, Laura Hummers, Fredrick Wigley, Cynthia Anderson, Francesco Boin, Ami Shah

Research output: Contribution to journalArticle

Abstract

Objective. We sought to retrospectively review a single-center experience using intravenous immunoglobulin (IVIG) for the treatment of refractory, active diffuse cutaneous systemic sclerosis (dcSSc). Methods. The mean modified Rodnan Skin score (mRSS) at baseline was compared to the mRSS at 6, 12, 18, and 24 months post-IVIG initiation by the paired Student t test. Changes in mRSS at 6 and 12 months were also compared to data from historical controls of 3 large, negative, multicenter, randomized clinical trials of other medications [D-penicillamine (D-pen), recombinant human relaxin (relaxin), and oral bovine type I collagen (collagen)] and to patients treated with mycophenolate mofetil (MMF) alone using the Student t test. Results. Thirty patients were treated with adjunctive IVIG (2 g/kg/mo) for refractory, active dcSSc. The mean baseline mRSS of our cohort was 29.6 ± 7.2, and this significantly decreased to 24.1 ± 9.6 (n = 29, p = 0.0011) at 6 months, 22.5 ± 10.0 (n = 25, p = 0.0001) at 12 months, 20.6 ± 11.8 (n = 23, p = 0.0001) at 18 months, and 15.3 ± 6.4 (n = 15, p <0.0001) at 24 months. The mean change in mRSS at 6 months was not significantly different in the IVIG group (-5.3 ± 7.9) compared to the relaxin trial (-4.8 ± 6.99, p = 0.74) or MMF group (-3.4 ± 7.4, p = 0.26); however, at 12 months, the mean change in mRSS was significantly better in the IVIG group (-8 ± 8.3) than in the D-pen (-2.47 ± 8.6, p = 0.005) and collagen (-3.4 ± 7.12, p = 0.005) groups, and was comparable to the group of primary MMF responders (-7.1 ± 9, p = 0.67). Conclusion. Our observational study suggests that IVIG may be an effective adjunctive therapy for active dcSSc in patients failing other therapies.

Original languageEnglish (US)
Pages (from-to)236-242
Number of pages7
JournalJournal of Rheumatology
Volume42
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Diffuse Scleroderma
Intravenous Immunoglobulins
Mycophenolic Acid
Relaxin
Skin
Penicillamine
Collagen
Therapeutics
Students
Collagen Type I
Observational Studies
Randomized Controlled Trials

Keywords

  • D
  • I
  • S

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. / Poelman, Corrie L.; Hummers, Laura; Wigley, Fredrick; Anderson, Cynthia; Boin, Francesco; Shah, Ami.

In: Journal of Rheumatology, Vol. 42, No. 2, 01.02.2015, p. 236-242.

Research output: Contribution to journalArticle

@article{021b48220c504498a1da3e2dc73a64cb,
title = "Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis",
abstract = "Objective. We sought to retrospectively review a single-center experience using intravenous immunoglobulin (IVIG) for the treatment of refractory, active diffuse cutaneous systemic sclerosis (dcSSc). Methods. The mean modified Rodnan Skin score (mRSS) at baseline was compared to the mRSS at 6, 12, 18, and 24 months post-IVIG initiation by the paired Student t test. Changes in mRSS at 6 and 12 months were also compared to data from historical controls of 3 large, negative, multicenter, randomized clinical trials of other medications [D-penicillamine (D-pen), recombinant human relaxin (relaxin), and oral bovine type I collagen (collagen)] and to patients treated with mycophenolate mofetil (MMF) alone using the Student t test. Results. Thirty patients were treated with adjunctive IVIG (2 g/kg/mo) for refractory, active dcSSc. The mean baseline mRSS of our cohort was 29.6 ± 7.2, and this significantly decreased to 24.1 ± 9.6 (n = 29, p = 0.0011) at 6 months, 22.5 ± 10.0 (n = 25, p = 0.0001) at 12 months, 20.6 ± 11.8 (n = 23, p = 0.0001) at 18 months, and 15.3 ± 6.4 (n = 15, p <0.0001) at 24 months. The mean change in mRSS at 6 months was not significantly different in the IVIG group (-5.3 ± 7.9) compared to the relaxin trial (-4.8 ± 6.99, p = 0.74) or MMF group (-3.4 ± 7.4, p = 0.26); however, at 12 months, the mean change in mRSS was significantly better in the IVIG group (-8 ± 8.3) than in the D-pen (-2.47 ± 8.6, p = 0.005) and collagen (-3.4 ± 7.12, p = 0.005) groups, and was comparable to the group of primary MMF responders (-7.1 ± 9, p = 0.67). Conclusion. Our observational study suggests that IVIG may be an effective adjunctive therapy for active dcSSc in patients failing other therapies.",
keywords = "D, I, S",
author = "Poelman, {Corrie L.} and Laura Hummers and Fredrick Wigley and Cynthia Anderson and Francesco Boin and Ami Shah",
year = "2015",
month = "2",
day = "1",
doi = "10.3899/jrheum.140833",
language = "English (US)",
volume = "42",
pages = "236--242",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis

AU - Poelman, Corrie L.

AU - Hummers, Laura

AU - Wigley, Fredrick

AU - Anderson, Cynthia

AU - Boin, Francesco

AU - Shah, Ami

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective. We sought to retrospectively review a single-center experience using intravenous immunoglobulin (IVIG) for the treatment of refractory, active diffuse cutaneous systemic sclerosis (dcSSc). Methods. The mean modified Rodnan Skin score (mRSS) at baseline was compared to the mRSS at 6, 12, 18, and 24 months post-IVIG initiation by the paired Student t test. Changes in mRSS at 6 and 12 months were also compared to data from historical controls of 3 large, negative, multicenter, randomized clinical trials of other medications [D-penicillamine (D-pen), recombinant human relaxin (relaxin), and oral bovine type I collagen (collagen)] and to patients treated with mycophenolate mofetil (MMF) alone using the Student t test. Results. Thirty patients were treated with adjunctive IVIG (2 g/kg/mo) for refractory, active dcSSc. The mean baseline mRSS of our cohort was 29.6 ± 7.2, and this significantly decreased to 24.1 ± 9.6 (n = 29, p = 0.0011) at 6 months, 22.5 ± 10.0 (n = 25, p = 0.0001) at 12 months, 20.6 ± 11.8 (n = 23, p = 0.0001) at 18 months, and 15.3 ± 6.4 (n = 15, p <0.0001) at 24 months. The mean change in mRSS at 6 months was not significantly different in the IVIG group (-5.3 ± 7.9) compared to the relaxin trial (-4.8 ± 6.99, p = 0.74) or MMF group (-3.4 ± 7.4, p = 0.26); however, at 12 months, the mean change in mRSS was significantly better in the IVIG group (-8 ± 8.3) than in the D-pen (-2.47 ± 8.6, p = 0.005) and collagen (-3.4 ± 7.12, p = 0.005) groups, and was comparable to the group of primary MMF responders (-7.1 ± 9, p = 0.67). Conclusion. Our observational study suggests that IVIG may be an effective adjunctive therapy for active dcSSc in patients failing other therapies.

AB - Objective. We sought to retrospectively review a single-center experience using intravenous immunoglobulin (IVIG) for the treatment of refractory, active diffuse cutaneous systemic sclerosis (dcSSc). Methods. The mean modified Rodnan Skin score (mRSS) at baseline was compared to the mRSS at 6, 12, 18, and 24 months post-IVIG initiation by the paired Student t test. Changes in mRSS at 6 and 12 months were also compared to data from historical controls of 3 large, negative, multicenter, randomized clinical trials of other medications [D-penicillamine (D-pen), recombinant human relaxin (relaxin), and oral bovine type I collagen (collagen)] and to patients treated with mycophenolate mofetil (MMF) alone using the Student t test. Results. Thirty patients were treated with adjunctive IVIG (2 g/kg/mo) for refractory, active dcSSc. The mean baseline mRSS of our cohort was 29.6 ± 7.2, and this significantly decreased to 24.1 ± 9.6 (n = 29, p = 0.0011) at 6 months, 22.5 ± 10.0 (n = 25, p = 0.0001) at 12 months, 20.6 ± 11.8 (n = 23, p = 0.0001) at 18 months, and 15.3 ± 6.4 (n = 15, p <0.0001) at 24 months. The mean change in mRSS at 6 months was not significantly different in the IVIG group (-5.3 ± 7.9) compared to the relaxin trial (-4.8 ± 6.99, p = 0.74) or MMF group (-3.4 ± 7.4, p = 0.26); however, at 12 months, the mean change in mRSS was significantly better in the IVIG group (-8 ± 8.3) than in the D-pen (-2.47 ± 8.6, p = 0.005) and collagen (-3.4 ± 7.12, p = 0.005) groups, and was comparable to the group of primary MMF responders (-7.1 ± 9, p = 0.67). Conclusion. Our observational study suggests that IVIG may be an effective adjunctive therapy for active dcSSc in patients failing other therapies.

KW - D

KW - I

KW - S

UR - http://www.scopus.com/inward/record.url?scp=84923174987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923174987&partnerID=8YFLogxK

U2 - 10.3899/jrheum.140833

DO - 10.3899/jrheum.140833

M3 - Article

C2 - 25433527

AN - SCOPUS:84923174987

VL - 42

SP - 236

EP - 242

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -